CGM Devices for Biohackers Ranked: What the Evidence Actually Shows

Continuous glucose monitors, once reserved for diabetic patients, have become a cornerstone tool in the longevity biohacking community. The appeal is intuitive: real-time glucose data could help individuals identify metabolic triggers, reduce insulin resistance, and theoretically support mitochondrial health. But how well do these devices actually deliver on those promises for healthy adults?

Recent expert reviews from longevity-focused sources evaluated six major CGM products and platforms — Dexcom G7, Freestyle Libre, Medtronic Guardian 3, Levels, Veri, and Nutrisense — across dimensions of accuracy, cost, wearability, and evidence quality. Dexcom G7 emerged as the top-rated device, praised for its 10–14 day sensor life and seamless integration with popular wearables. Freestyle Libre was highlighted as a solid budget alternative, while app-based platforms like Levels and Nutrisense were noted for adding coaching layers to raw glucose data.

Despite enthusiastic endorsements from high-profile physicians like Peter Attia and David Sinclair, the evidence base for CGM use in metabolically healthy individuals is notably thin. Research from Mass General Brigham found weak correlations between CGM-measured glucose variability and HbA1c in non-diabetics, undermining claims that these devices can reliably predict long-term metabolic risk. Critics also raise concerns about over-optimization, anxiety, and the biological complexity that no wearable can fully capture.

The practical consensus from reviewers is cautious but not dismissive. Short-term trials of 2–4 weeks are recommended to identify personalized food, exercise, and stress responses without fostering unhealthy fixation on glucose numbers. Costs range from $50 to $400 per month out-of-pocket for non-diabetics, as insurance rarely covers these devices for healthy users.

For clinicians and health-conscious individuals, CGMs appear most valuable as behavioral feedback tools rather than diagnostic instruments. The technology is promising, but the longevity-specific evidence remains largely anecdotal and expert-driven rather than grounded in robust randomized controlled trials.